重症患者阶梯式肠内营养补充蛋白质(REPLENISH)随机临床试验的统计分析计划
REPLENISH试验为多中心随机对照试验,纳入2502例成人重症机械通气患者,比较在标准肠内营养基础上补充肠内蛋白质以达到高蛋白量(2-2.4 g/kg/天)与不补充蛋白质以维持中等蛋白量(0.8-1.2 g/kg/天)对90天全因死亡率的影响;本统计分析计划依据国际指南规定主要和次要结局及亚组的分析方法,以确保无偏分析。
要点
- 补充肠内蛋白质组目标为2-2.4 g/kg/天,对照组目标为0.8-1.2 g/kg/天。
- 主要结局为90天全因死亡率,样本量2502例,有80%把握度检测死亡率从30%降至25%的5%绝对风险降低。
- 次要结局包括90天功能评估和健康相关生活质量评估。
核心结论
- 本统计分析计划规定了REPLENISH试验主要和次要结局及亚组的评价方法,应用该计划将有助于对临床数据进行无偏分析。
研究设计与样本
- 多中心随机临床试验,计划纳入2502例成人重症机械通气患者,随机接受补充肠内蛋白质(1.2 g/kg/天)加标准肠内营养以达到高蛋白量(2-2.4 g/kg/天)或不补充肠内蛋白质以达到中等蛋白量(0.8-1.2 g/kg/天)。
主要发现
- 样本量2502例有80%把握度检测90天死亡率从30%降至25%的5%绝对风险降低。
- 主要结局为90天全因死亡率;其他结局包括90天功能评估和健康相关生活质量评估。
关键数值与推荐
- 补充肠内蛋白质组目标蛋白量为2-2.4 g/kg/天,对照组为0.8-1.2 g/kg/天。
- 主要结局90天全因死亡率拟检测从30%降至25%的绝对风险降低5%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal amount and timing of protein intake in critically ill patients are unknown. REPLENISH (Replacing Protein via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients) trial evaluates whether supplemental enteral protein added to standard enteral nutrition to achieve a high amount of enteral protein given from ICU day five until ICU discharge or ICU day 90 as compared to no supplemental enteral protein to achieve a moderate amount of enteral protein would reduce all-cause 90-day mortality in adult critically ill mechanically ventilated patients. METHODS: In this multicenter randomized trial, critically ill patients will be randomized to receive supplemental enteral protein (1.2 g/kg/day) added to standard enteral nutrition to achieve a high amount of enteral protein (range of 2-2.4 g/kg/day) or no supplemental enteral protein to achieve a moderate amount of enteral protein (0.8-1.2 g/kg/day). The primary outcome is 90-day all-cause mortality; other outcomes include functional and health-related quality-of-life assessments at 90 days. The study sample size of 2502 patients will have 80% power to detect a 5% absolute risk reduction in 90-day mortality from 30 to 25%. Consistent with international guidelines, this statistical analysis plan specifies the methods for evaluating primary and secondary outcomes and subgroups. Applying this statistical analysis plan to the REPLENISH trial will facilitate unbiased analyses of clinical data. CONCLUSION: Ethics approval was obtained from the institutional review board, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia (RC19/414/R). Approvals were also obtained from the institutional review boards of each participating institution. Our findings will be disseminated in an international peer-reviewed journal and presented at relevant conferences and meetings. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04475666 . Registered on July 17, 2020.
引用
- Arabi YM, Al-Dorzi HM, Aldibaasi O, et al. Statistical analysis plan for the replacing protein via enteral nutrition in a stepwise approach in critically ill patients (REPLENISH) randomized clinical trial. Trials. 2024. PMID: 38698442. doi:10.1186/s13063-024-08105-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。